{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:21:07Z","timestamp":1790702467464,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1053\/j.semnuclmed.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T03:46:22Z","timestamp":1449891982000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Advances in Peptide Receptor Radionuclide Therapy"],"prefix":"10.1053","volume":"46","author":[{"given":"Amir","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Biersack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2015.09.005_bib1","first-page":"343","article-title":"Chemotherapy of endocrine malignancies: A review","volume":"14","author":"Kvols","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib2","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib5","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2014well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semnuclmed.2009.11.004","article-title":"131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors","volume":"40","author":"Grunwald","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib13","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib14","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2967\/jnumed.112.119313","article-title":"Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors","volume":"54","author":"Ezziddin","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib18","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib21","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: First clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib24","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib25","first-page":"1929","article-title":"d-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake","volume":"38","author":"Bernard","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib26","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","article-title":"End-stage renal disease after treatment with 90Y-DOTATOC","volume":"28","author":"Cybulla","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib28","first-page":"617","article-title":"New advances in peptide receptor radionuclide therapy","volume":"43","author":"de Jong","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib29","first-page":"1310","article-title":"Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC","volume":"46","author":"Forrer","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib31","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib32","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1667\/0033-7587(2003)159[0182:TNOADI]2.0.CO;2","article-title":"The nonuniformity of antibody distribution in the kidney and its influence on dosimetry","volume":"159","author":"Flynn","year":"2003","journal-title":"Radiat Res"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3413\/Nukmed-0428-11-08","article-title":"Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy","volume":"51","author":"Sabet","year":"2012","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00259-006-0232-1","article-title":"Long-term toxicity of [177Lu-DOTA0, Tyr3]octreotate in rats","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib37","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib39","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/cbr.2006.353","article-title":"From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging","volume":"22","author":"Forrer","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","article-title":"Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib44","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00259-013-2547-z","article-title":"Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snuc.2002.31563","article-title":"Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology Group","volume":"32","author":"Chinol","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib48","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cbr.2012.1195","article-title":"Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"27","author":"Gupta","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib50","first-page":"1725","article-title":"Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison","volume":"45","author":"Wessels","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib51","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr(3)-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib52","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","article-title":"Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate","volume":"36","author":"Forrer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib53","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-Octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib54","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib55","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib56","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3413\/Nukmed-0614-13-08","article-title":"Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement","volume":"53","author":"Sabet","year":"2014","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-010-1610-2","article-title":"Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy","volume":"38","author":"Ezziddin","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib61","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","article-title":"Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine","volume":"42","author":"Sabet","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib62","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib63","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y\/177Lu-DOTATATE: Which is a better therapy option?","volume":"38","author":"Kunikowska","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1196\/annals.1294.026","article-title":"Peptide receptor radionuclide therapy","volume":"1014","author":"Krenning","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib65","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2967\/jnumed.109.068957","article-title":"Salvage therapy with 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"van Essen","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib66","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00259-015-3105-7","article-title":"Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC","volume":"42","author":"Severi","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib67","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.3748\/wjg.15.5867","article-title":"Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor","volume":"15","author":"Kaemmerer","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib68","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00259-011-1835-8","article-title":"Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)","volume":"38","author":"Sowa-Staszczak","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejso.2011.08.129","article-title":"The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable","volume":"38","author":"Barber","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/RLU.0b013e318238f111","article-title":"Neoadjuvant downsizing by internal radiation: A case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors","volume":"37","author":"Ezziddin","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib71","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0, Tyr3]Octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib72","first-page":"334","article-title":"The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber","volume":"68","author":"Lien","year":"1970","journal-title":"Surgery"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib73","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00259-008-0779-0","article-title":"Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases","volume":"35","author":"Limouris","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib74","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1148\/radiol.2372041203","article-title":"Large-volume liver metastases from neuroendocrine tumors: Hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy","volume":"237","author":"McStay","year":"2005","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/ERC-11-0144","article-title":"Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases","volume":"18","author":"Kratochwil","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib76","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2967\/jnumed.108.061457","article-title":"Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues","volume":"50","author":"Waser","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2191-219X-3-82","volume":"3","author":"Sabet","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib78","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00259-004-1697-4","article-title":"68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5","volume":"32","author":"Wild","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib79","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1210\/jc.2009-2487","article-title":"Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients","volume":"95","author":"Reubi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib80","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1210\/en.2006-1266","article-title":"Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2","volume":"148","author":"Sharif","year":"2007","journal-title":"Endocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib81","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib82","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2967\/jnumed.111.095778","article-title":"Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro","volume":"52","author":"Cescato","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib83","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s00259-012-2231-8","article-title":"Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy","volume":"39","author":"Wang","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib84","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib85","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","article-title":"Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors","volume":"14","author":"Miederer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nucmedbio.2006.11.006","article-title":"Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells","volume":"34","author":"Nayak","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib87","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib88","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(68)91058-1","article-title":"Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin","volume":"2","author":"Murray-Lyon","year":"1968","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib89","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib90","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib91","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-007-0688-7","article-title":"Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours","volume":"35","author":"van Essen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib93","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/cbr.2012.1276","article-title":"Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors","volume":"27","author":"Claringbold","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib94","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000362558","article-title":"Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up","volume":"99","author":"Kesavan","year":"2014","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib96","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib97","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","article-title":"Peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in advanced neuroendocrine tumors: Results from a Danish cohort treated in Switzerland","volume":"93","author":"Pfeifer","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2015.09.005_bib98","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299815001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299815001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T03:20:06Z","timestamp":1537154406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299815001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0001299815001063"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.09.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Peptide Receptor Radionuclide Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}